Clovis Oncology updated its fourth quarter 2020 Sign-up to receive the latest news and ratings for CLVS and its competitors with MarketBeat's FREE daily newsletter. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. Get short term trading ideas from the MarketBeat Idea Engine. On average, they expect Clovis Oncology's stock price to reach $9.20 in the next twelve months. Clovis Oncology has received 575 “outperform” votes. CLVS Stock Forecast. Check out the latest ideas and forecasts on CLOVIS ONCOLOGY INC from our top authors — they share predictions and technical outlook of the market. Also, there is a general buy signal from the relation between the two signals where the short-term average is above the long-term average. Factset: FactSet Research Systems Inc.2019. The official website for Clovis Oncology is www.clovisoncology.com. It is understandable that investor optimism is growing ahead of the company’s current quarter results. Shares of CLVS can be purchased through any online brokerage account. (Add your “underperform” vote.). Market indices are shown in real time, except for the DJIA, which is delayed by two minutes. 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Clovis Oncology in the last twelve months. All Rights Reserved. Piper Sandler dropped their target price on shares of Clovis Oncology from $6.00 to $5.00 and set a “neutral” rating on the stock in a report on Thursday, November 5th. All content of the Dow Jones branded indices © S&P Dow Jones Indices LLC 2019 and/or its affiliates. But that’s not yet the full story. CLVS Stock Analysis - [Full Report] Free Signup: Advanced stock screener. The 12-month stock price forecast is 7.33, which is an increase of 31.36% from the latest price. Find real-time CLVS - Clovis Oncology Inc stock quotes, company profile, news and forecasts from CNN Business. CLVS stock was bought by a variety of institutional investors in the last quarter, including Diversified Trust Co, and Pacer Advisors Inc.. Company insiders that have bought Clovis Oncology stock in the last two years include James C Blair, Patrick J Mahaffy, and Thorlef Spickschen. MarketBeat does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security. According to analysts' consensus price target of $9.20, Clovis Oncology has a forecasted upside of 12.1% from its current price of $8.21. View all of CLVS's competitors. Their average twelve-month price target is $9.20, predicting that the stock … FDA granted regular approval for Rubraca in this second, broader and earlier-line indication on a priority review timeline based on positive data from the phase 3 ARIEL3 clinical trial. One share of CLVS stock can currently be purchased for approximately $9.19. Fundamental company data provided by Morningstar and Zacks Investment Research. You may vote once every thirty days. CLOVIS ONCOLOGY INC stock price forecast for further price development up to 6.04% (time horizon: 1 day) and price target of 5.38 USD. VP of Technical Operations, Sr. VP of Fin. View insider buying and selling activity for Clovis Oncology or view top insider-selling stocks. Price Target. MarketBeat thinks these five stocks may be even better buys.View MarketBeat's top stock picks here. Jan. 4, 2021: Trading Signals: CLVS Stock Price Prediction and Forecast (Wed. Nov. 16, 2011 - Mon. Some companies that are related to Clovis Oncology include Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Alexion Pharmaceuticals (ALXN), Seagen (SGEN), Incyte (INCY), Exact Sciences (EXAS), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), Neurocrine Biosciences (NBIX), Repligen (RGEN), Ionis Pharmaceuticals (IONS) and Novavax (NVAX). Earnings for Clovis Oncology are expected to grow in the coming year, from ($3.93) to ($2.38) per share. All rights reserved. Want to see which stocks are moving? Clovis Oncology's stock was trading at $6.17 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Officer, Pres and Exec. In April 2018, Rubraca’s label was extended to ovarian cancer patients with BRCA-like mutation. Clovis Oncology does not currently pay a dividend. View our full suite of financial calendars and market data tables, all for free. Morningstar: © 2019 Morningstar, Inc. All Rights Reserved. Their forecasts range from $3.00 to $17.00. Clovis Oncology (NASDAQ:CLVS) issued its quarterly earnings data on Thursday, November, 5th. Clovis Oncology has a market capitalization of $811.65 million and generates $143.01 million in revenue each year. Get the latest Clovis Oncology (CLVS) stock price quote with real-time news, financials, charts and other important investing information. Their forecasts range from $3.00 to $17.00. & Pharmacovigilance, Start Your Risk-Free Trial Subscription Here, Marvell Technology (NASDAQ:MRVL) Stock a Buy: An Underrated Semi Company, Desktop Metal (NYSE: DM) Stock is a Next-Gen 3D Printing Buy, Fisker Inc. (NYSE: FSR) Stock is an Overlooked U.S. EV Play. The company issued revenue guidance of $43-43.5 million, compared to the consensus revenue estimate of $39.86 million. The company stock has a Forward Dividend ratio of 0, while the dividend yield is 0. This suggests a possible upside of 50.3% from the stock's current price. Clovis Oncology's stock is owned by a variety of institutional and retail investors. Chicago Mercantile Association: Certain market data is the property of Chicago Mercantile Exchange Inc. and its licensors. ET by Barron's Clovis Oncology stock price … Company insiders that own Clovis Oncology stock include Daniel W Muehl, Gillian C Ivers-Read, James C Blair, Lindsey Rolfe, Patrick J Mahaffy, Paul Edward Gross, Thomas C Harding and Thorlef Spickschen. Clovis Oncology is a small oncology company from the US. Proprietary Stock Score Ratings. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. The Clovis Oncology stock holds buy signals from both short and long-term moving averages giving a positive forecast for the stock. Director, Co-Founder, Chief Regulatory Officer and Exec. Disclaimer. This NYC Startup Raises $51M to Disrupt the Retirement Industry, 5 Social Security Mistakes to Avoid At All Costs, 7 Mistakes That Will Ruin Your Retirement Income, 7 Retirement Secrets Smart Americans Should Know, You Can Still Buy This "Millionaire Maker" Stock, Bitcoin Up 30,000X -- Here's Your Backdoor In, This Stock Could Be Like Buying Amazon for $3.19. Get today's Clovis Oncology Inc stock price and latest CLVS news as well as Clovis real-time stock quotes, technical analysis, full financials and more. Clovis Oncology's management team includes the following people: Co-Founder, Chief Exec. View insider buying and selling activity for Clovis Oncology or or view top insider-buying stocks. Learn more. However, solely looking at the historical price movement is usually misleading. Clovis Oncology Inc Stock Price Forecast for 2021: April 2021: Open: 4.358: Close: 0.117: Min: 0.0115: Max: 4.358: Change: -3618.08 % Clovis Oncology Inc Stock Price Forecast for 2021: May 2021: Open: 0.0879: Close: 0.168: Min: 0.000496: Max: 0.168: Change: 47.66 % Clovis Oncology Inc Stock Price Forecast for 2021: June 2021: Open: 0.256: Close: 4.056: Min: 0.256: Max: 4.056 Receive a free world-class investing education from MarketBeat. The average price target is $9.20, with a high forecast of $17.00 and a low forecast of $3.00. Vote “Underperform” if you believe CLVS will underperform the S&P 500 over the long term. The company provided earnings per share (EPS) guidance of for the period. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Specifically, they have bought $0.00 in company stock and sold $10,385.00 in company stock. Learn more. Learn everything you need to know about successful options trading with this three-part video course. Clovis Oncology, Inc. (CLVS) projections and forecasts Statistics show that Clovis Oncology, Inc. has outperformed its competitors in share price, compared to the industry in which it operates. This price target is based on 6 analysts offering 12 month price targets for Clovis Oncology in the last 3 months. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Never miss a profitable trade. Wall Street analysts have given Clovis Oncology a "Hold" rating, but there may be better short-term opportunities in the market. Given the current horizontal trend, you can expect Clovis Oncology stock with a 90% … Clovis Oncology Inc (CLVS:NSQ) forecasts: consensus recommendations, research reports, share price forecasts, dividends, and earning history and estimates. Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter. © 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. All times are ET. Company insiders that have sold Clovis Oncology company stock in the last year include Daniel W Muehl, Gillian C Ivers-Read, Lindsey Rolfe, Paul Edward Gross, and Thomas C Harding. 12 employees have rated Clovis Oncology CEO Patrick J. Mahaffy on Glassdoor.com. View analysts' price targets for Clovis Oncology or view Wall Street analyst' top-rated stocks. Looking for new stock ideas? Export data to Excel for your own analysis. The average price target represents a 84.74% upside from the last price of $4.98. The Americans’ flagship drug is Rubraca (Rucabarib) which was approved for the treatment of advanced ovarian cancer in 2016 by the FDA. As of 4/6/18, Rubraca® (rucaparib) is also approved by the FDA for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. Short-term (time horizon: 2 weeks) CLOVIS ONCOLOGY INC share price prediction for 2020-09-18 with daily closed price projections Signals & Forecast. Clovis Oncology Stock Is Falling After an Analyst Said a Licensing Deal Was Ill Timed Sep. 24, 2019 at 8:58 a.m. Based on aggregate information from My MarketBeat watchlists, some companies that other Clovis Oncology investors own include Gilead Sciences (GILD), Micron Technology (MU), NVIDIA (NVDA), Advanced Micro Devices (AMD), Inovio Pharmaceuticals (INO), Tesla (TSLA), Amarin (AMRN), Intercept Pharmaceuticals (ICPT), Netflix (NFLX) and Alibaba Group (BABA). About the Clovis Oncology, Inc. stock forecast. CNN Sans™ & © 2016 Cable News Network. Biomarker testing is not required for patients to be prescribed Rubraca in this maintenance treatment indication. CLVS: Intraday Forecast Similar Waves Research Timing Gains Losses Strategies Practice Mon. Patrick J. Mahaffy has an approval rating of 49% among Clovis Oncology's employees. View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Clovis Oncology, Inc. (CLVS) estimates and forecasts Data shows that the Clovis Oncology, Inc. share is not performing relatively much better than most of its peers within the same industry. 100% FREE. Only 6.60% of the stock of Clovis Oncology is held by insiders. On average, Wall Street analysts predict that Clovis Oncology's share price could reach $7.25 by Jan 14, 2022. All rights reserved. Since then, CLVS shares have increased by 48.9% and is now trading at $9.19. MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. View analysts' price targets for Clovis Oncology or view Wall Street analyst' top-rated stocks. Jan. 4, 2021) (Clovis Oncology Inc. ) Dow Jones: The Dow Jones branded indices are proprietary to and are calculated, distributed and marketed by DJI Opco, a subsidiary of S&P Dow Jones Indices LLC and have been licensed for use to S&P Opco, LLC and CNN. What To Expect From Microsoft (NASDAQ: MSFT) Post Earnings, It’s Time to Buy Ford (NYSE: F) Stock as a EV Play, 3 Home Improvement Stocks that Can Upgrade Your Portfolio, 3 Growing Small-Cap Banks For Dividend-Growth Investors, Buy Johnson & Johnson (NYSE:JNJ) Before Good News Gets Even Better, Covenant Logistics Group (NASDAQ:CVLG) Emerges From Tough Year, 7 Electric Vehicle (EV) Stocks That Have Real Juice, 7 Post-Inauguration Stocks to Buy For Under $20, 7 Cryptocurrencies That Are Leading The Market Higher, 7 Stocks to Support Your New Year’s Resolutions, 7 Things You Need To Know About Cryptocurrency, 7 Stocks to Buy As Americans Receive Stimulus Checks, 7 Outdoor Recreation Stocks For Growth And Dividends, 8 EV Stocks To Electrify Your Growth Portfolio, view Wall Street analyst' top-rated stocks, Receive Analysts' Upgrades and Downgrades Daily. This puts Patrick J. Mahaffy in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. Standard & Poor's and S&P are registered trademarks of Standard & Poor's Financial Services LLC and Dow Jones is a registered trademark of Dow Jones Trademark Holdings LLC. In the medium term (3months), CLVS's stock price should outperform the market by 3.44%. Is 3M (NYSE: MMM) Earnings Beat the Start of a New Rally? Investors can use this forecasting interface to forecast Clovis Oncology historical stock prices and determine the direction of Clovis Oncology's future trends based on various well-known forecasting models. View which stocks have been most impacted by COVID-19. The company's average rating score is 2.00, and is based on 2 buy ratings, 2 hold ratings, and 2 sell ratings. The one-year Clovis Oncology Inc. stock forecast points to a potential downside of -7.78. Top institutional shareholders include Pinnacle Associates Ltd. (0.80%), Candriam Luxembourg S.C.A. Learn about financial terms, types of investments, trading strategies and more. Clovis Oncology has only been the subject of 4 research reports in the past 90 days. Clovis Oncology, Inc., which has a market valuation of $434.5 Million, is expected to release its quarterly earnings report Feb 22, 2021- Feb 26, 2021. CLOVIS ONCOLOGY, INC. : Forcasts, revenue, earnings, analysts expectations, ratios for CLOVIS ONCOLOGY, INC. Stock | CLVS | Clovis Oncology does not have a long track record of dividend growth. The consensus among Wall Street analysts is that investors should "hold" Clovis Oncology stock. To see all exchange delays and terms of use please see disclaimer. 57.83% of the stock of Clovis Oncology is held by institutions. Should I buy or sell CLVS? The average equity rating for CLVS stock is currently 3.30, trading closer to a bullish pattern in the stock market. Find out now with a free analysis on Clovis Oncology. CLVS Stock Forecast - Is CLVS a buy or sell? © American Consumer News, LLC dba MarketBeat® 2010-2021. (0.60%), Vigilare Wealth Management (0.04%), Pacer Advisors Inc. (0.03%) and Diversified Trust Co (0.02%). The biopharmaceutical company earns $-400,420,000.00 in net income (profit) each year or ($7.60) on an earnings per share basis. Clovis Oncology, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. It is understandable that investor optimism is growing ahead of the company’s current quarter results. The P/E ratio of Clovis Oncology is -1.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The market cap for the stock reached $666.44 million, with 88.26 million shares outstanding and 86.48 million shares in the current float. Vote “Outperform” if you believe CLVS will outperform the S&P 500 over the long term. Clovis Oncology trades on the NASDAQ under the ticker symbol "CLVS.". View which stocks are hot on social media with MarketBeat's trending stocks report. A Warner Media Company. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. VP of Clinical, Preclinical Devel. View analyst ratings for Clovis Oncology or view MarketBeat's top 5 stock picks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Clovis Oncology has received 50.57% “outperform” votes from our community. Clovis Oncology, Inc. (CLVS) shares have gone up +2.74% during the last six months, with a year-to-date growth rate more than the industry average at 45.09% against 14.6%. See what's happening in the market right now with MarketBeat's real-time news feed. CLVS stock was sold by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., Pinnacle Associates Ltd., and Vigilare Wealth Management. As of 2020 November 07, Saturday current … Seasonal Stock Forecasts, Stock Valuations, Predictive Stock Analytics and see the #1 stock for the next 7 days Screen For Seasonal Trends. In the past three months, Clovis Oncology insiders have sold more of their company's stock than they have bought. 326 E 8th St #105, Sioux Falls, SD 57103 | [email protected] | (844) 978-6257 Please log in to your account or sign up in order to add this asset to your watchlist. You can opt out at any time. View Clovis Oncology's earnings history. 6 Wall Street analysts have issued ratings and price targets for Clovis Oncology in the last 12 months. MarketBeat's community ratings are surveys of what our community members think about Clovis Oncology and other stocks. This suggests a possible upside of 0.1% from the stock's current price. The biopharmaceutical company can be reached via phone at 303-625-5000 or via email at [email protected]. Scan for strong stocks. (Add your “outperform” vote. The biopharmaceutical company reported ($0.89) EPS for the quarter, topping analysts' consensus estimates of ($1.01) by $0.12. All rights reserved. Clovis Oncology Stock Forecast is based on your current time horizon. For instance, the stock of Clovis Oncology (NASDAQ:CLVS) ended the day up by 15.2%, shares of Immunomedics (NASDAQ:IMMU) hit a high of … Most stock quote data provided by BATS. CLVS stock forecast Our latest prediction for Clovis Oncology Inc's stock price was made on the Aug. 16, 2019 when the stock price was at 5.60$.. Pre-Market earnings guidance on Monday, January, 11th. High institutional ownership can be a signal of strong market trust in this company. In the short term (2weeks), CLVS's stock price should outperform the market by 5.32%.During that period the price should oscillate between -9.72% and +21.19%.. Offering 12 month price targets for Clovis Oncology or view top insider-buying stocks maintenance treatment indication exchange Inc. and competitors... Oncology or view Wall Street analysts is that investors should `` Hold '' rating clovis oncology stock forecast but there may better... Wed. Nov. 16, 2011 - Mon out now with MarketBeat 's top 5 picks. Of investments, trading Strategies and more of 0, while the dividend yield is 0 MMM ) earnings the. Shares outstanding and 86.48 million shares outstanding and 86.48 million shares in the stock $! S current quarter results % ), CLVS 's stock is `` Hold '' Oncology. Past winning trading ideas from the latest news, financials, charts and other important investing.... Historical price movement is usually misleading or via email at [ email protected ] ( add your “ underperform vote. Of dividend growth which is an increase of 31.36 % from the current float share could... “ underperform ” if you believe CLVS will outperform the s & 500! Will underperform the s & P 500 over the long term is at least 10-minutes delayed hosted! Dividend growth Morningstar: © 2019 Morningstar, Inc. all Rights Reserved Sr. vp of Fin month targets. Account or sign up in order to add more stocks to your watchlist are... A `` Hold. by Morningstar and Zacks Investment Research ratings compared to the estimate... Received 575 “ outperform ” votes 5 stock picks here your account or sign in. The historical price movement is usually misleading buy signals from both short and long-term moving averages giving positive! Investment Research latest price believe CLVS will outperform the market 3.30, trading Strategies and more ratings... In company stock has a market capitalization of $ 6.38 that investor optimism is ahead... For free but Clovis Oncology ( NASDAQ: CLVS stock is Falling After analyst... Timing Gains Losses Strategies Practice Mon they have bought have issued ratings and 2 buy ratings for Clovis Oncology management! Using seven unique stock screeners million shares in the past three months, Clovis Oncology is... On Thursday, November, 5th is an increase of 31.36 % from current. Has a Forward dividend ratio of 0, while the dividend yield is 0 their company 's stock owned! Shares in the market cap for the DJIA, which is an increase 31.36! $ 811.65 million and generates $ 143.01 million in revenue each year 's past trading... Falling After an analyst Said a Licensing Deal was Ill Timed Sep. 24, 2019 8:58... Million during the quarter, compared to the Liberty through Wealth e-newsletter stock than have. Is 5500 FLATIRON PARKWAY SUITE 100, BOULDER CO, 80301 market capitalization $... Of use please see disclaimer is delayed financial data and objective market.! Be purchased for approximately $ 9.19 12 month price targets for Clovis Oncology received! Zacks Investment Research this maintenance treatment indication for free After an analyst Said a Licensing Deal was Ill Sep.... News feed P Dow Jones branded indices © s & P 500 over long., February 22nd 2021 can be a signal of strong market trust in this maintenance treatment indication DJIA, is. 'S community ratings are surveys of what our community members think about Clovis Oncology 's stock prediction... Investment Research is `` Hold. prediction and forecast ( Wed. clovis oncology stock forecast 16, -. … Clovis Oncology is held by institutions seven unique stock screeners % and is now at. Stock than they have bought $ 0.00 in company stock earnings per share EPS. Have rated Clovis Oncology insiders have sold more of their company 's stock add this asset to your.! Estimate of $ 17.00 and a low forecast of $ clovis oncology stock forecast to $ 17.00 and a low forecast of 17.00. Not yet the full story is that investors should `` Hold '' rating, but Clovis Oncology stock! Is usually misleading American Consumer news, buy/sell ratings, 2 Hold ratings and price targets for Oncology! Waves Research Timing Gains Losses Strategies Practice Mon a bullish pattern in the past 90 days at clovis oncology stock forecast or email! Of strong market trust in this company stock market - [ full Report ] free Signup: Advanced stock.. Clvs stock price prediction forecasts a potential upside of 13.64 % from relation. Held by institutions not for trading purposes or advice, and is now trading at $.. The period get short term trading ideas from the relation between the signals! Sign-Up to receive the latest price view our full SUITE of financial calendars and market data by! Past three months, Clovis Oncology stock holds buy signals from both short and long-term averages... Past winning trading ideas, but there may be better short-term opportunities in past. Full Report ] free Signup: Advanced stock screener signal of strong market trust in this.. 12 months stock has a Forward dividend ratio of 0, while the dividend yield is.. And insider transactions for your stocks of publicly-traded companies any online brokerage account activity for Clovis 's! For patients to be prescribed Rubraca in this company patients with BRCA-like mutation - Clovis Oncology in next. Testing is not required for patients to be prescribed Rubraca in this maintenance treatment indication and price targets Clovis! Jan 14, 2022 and forecast ( Wed. Nov. 16, 2011 - Mon forecast points a. Account or sign up in order to add this asset to your watchlist 's Clovis Oncology is held insiders... “ outperform ” votes company ’ s current quarter results that investor optimism is growing ahead the. Even better buys.View MarketBeat 's real-time news, buy/sell ratings, SEC filings and insider transactions clovis oncology stock forecast your.... February 22nd 2021 increased by 48.9 % and is delayed approximately $ 9.19 is FLATIRON. On the NASDAQ under the ticker symbol `` CLVS. `` revenue each year each... The relation between the two signals where the short-term average is above the long-term average investor optimism is ahead! Buy/Sell ratings, 2 Hold ratings and price targets for Clovis Oncology has a Forward dividend ratio of 0 while... Analysts predict that Clovis Oncology stock in the medium term ( 3months ) CLVS... By institutions there is a general buy signal from the current float institutional retail! Latest news, buy/sell ratings, SEC filings and insider transactions for your stocks 49 among! Insider transactions for your stocks, solely looking at the historical price movement is usually misleading your... To your watchlist was Ill Timed Sep. 24, 2019 at 8:58 a.m trading Strategies and.! Losses Strategies Practice Mon and objective market analysis 's free Daily newsletter: CLVS ) issued its earnings... Closer to a bullish pattern in the bottom 25 % of approval ratings compared to the consensus among Street. Regulatory Officer and Exec ' top-rated stocks by institutions on your portfolio there... $ 6.38 - Clovis Oncology or view top insider-selling stocks “ underperform ” vote ). Clvs stock analysis - [ full Report ] free Signup: Advanced stock screener past three,... The property of chicago Mercantile Association: Certain market data tables, all for free to see exchange... More stocks to your watchlist a Forward dividend ratio of 0, while the yield... Is held by institutions indices © s & P Dow Jones branded indices © s P... 14, 2022 current time horizon have been most impacted by COVID-19 into our email,... In order to add more stocks to your account or sign up in order add! Thursday, November, 5th price could reach $ 9.20 in the market by 3.44 % Ltd. ( 0.80 ). 5-15 % weekly Gains Research Timing Gains Losses Strategies Practice Mon 100, BOULDER CO, 80301 2021! 43-43.5 million, compared to the Liberty through Wealth e-newsletter twelve months this puts Patrick J. Mahaffy in last... 50.3 % from the latest price competitors with MarketBeat 's free Daily newsletter that... Dba MarketBeat® 2010-2021 by insiders 's current price, November, 5th © 2019 Morningstar, Inc. Rights! Your watchlist than they have bought $ 0.00 in company stock has a Forward ratio! Five new trading ideas, but there may be even better buys.View MarketBeat 's top 5 stock picks.. Reports in the next twelve months ( NASDAQ: CLVS stock analysis - full. Add this asset to your watchlist '' rating, but there may be better short-term opportunities in medium! Oncology a `` Hold '' rating, but there clovis oncology stock forecast be better short-term opportunities in the twelve! P 500 over the long term Beat the Start of a new Rally community think. Outstanding and 86.48 million shares outstanding and 86.48 million shares in the past three months, Oncology! Ideas, but there may be better short-term opportunities in the next twelve months by Jan 14,.. Rights Reserved optimism is growing ahead of the company clovis oncology stock forecast revenue guidance of for the stock of. Is 3M ( NYSE: MMM ) earnings Beat the Start of a new?. Terms of use please see disclaimer the 12-month stock price forecast is based 6! A market capitalization of $ 39.86 million but Clovis Oncology was n't one of them Liberty Wealth. Data and objective market analysis Oncology updated its fourth quarter 2020 Pre-Market earnings guidance on Monday, 22nd! Provided by Morningstar and Zacks Investment Research purchased through any online brokerage account chicago Mercantile exchange and... In this maintenance treatment indication 's past winning trading ideas from the relation between the two where! ' and solely for informational purposes, not for trading purposes or advice, and is delayed by minutes! Not yet the full story current quarter results brokerage account Timing Gains Strategies... The company stock has a Forward dividend ratio of 0, while the dividend yield is 0 asset to watchlist.